Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 12/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878902 | 0.78 | MEN1 (0.43) | HCAR2USP30HTT | |
| SCHEMBL4789856 | 0.77 | HCAR2 (0.39) | CDK2CCNA2CCNA1HCAR2TDP1 | |
| SCHEMBL28949900 | 0.68 | POLB (0.40) | — | |
| SCHEMBL17948808 | 0.66 | CCNA2 (0.60) | CDK2CCNA2CCNA1HCAR2USP30 | |
| SCHEMBL2374222 | 0.65 | DRD4 (0.67) | HCAR2USP30 | |
| SCHEMBL5867504 | 0.64 | CDK2 (0.71) | CDK2CCNA2CCNA1 | |
| SCHEMBL3346932 | 0.64 | USP30 (0.47) | CDK2CCNA2CCNA1HCAR2USP30 | |
| SCHEMBL71054 | 0.64 | DRD4 (0.52) | CDK2CCNA2CCNA1USP30 | |
| SCHEMBL90870 | 0.64 | DRD4 (0.48) | CDK2CCNA2CCNA1USP30HTT | |
| SCHEMBL90978 | 0.64 | DRD4 (0.48) | CDK2CCNA2CCNA1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410100-B2 | Pteridinone derivatives as PI3-kinases inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2114945-B1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| EP-2114945-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092831-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | PIK3CA, PDPK1, PIK3C3 | CDK2 207/4885CCNA2 1622/4885CCNA1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.